Nighttime short-acting beta-agonist (SABA) in asthma and COPD

W. Anderson (Aurora, United States of America), R. Gondalia (San Francisco, United States of America), H. Hoch (Aurora, United States of America), M. Barrett (San Francisco, United States of America), S. Szefler (Aurora, United States of America), D. Van Sickle (Madison, United States of America), D. Stempel (San Francisco, United States of America)

Source: International Congress 2019 – Impact of sleep-disordered breathing in other diseases
Session: Impact of sleep-disordered breathing in other diseases
Session type: Thematic Poster
Number: 859

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
W. Anderson (Aurora, United States of America), R. Gondalia (San Francisco, United States of America), H. Hoch (Aurora, United States of America), M. Barrett (San Francisco, United States of America), S. Szefler (Aurora, United States of America), D. Van Sickle (Madison, United States of America), D. Stempel (San Francisco, United States of America). Nighttime short-acting beta-agonist (SABA) in asthma and COPD. 859

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: